Arbutus Biopharma (NASDAQ:ABUS – Get Rating)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $6.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 109.79% from the company’s previous close. HC Wainwright also issued estimates for Arbutus Biopharma’s FY2027 earnings at ($0.11) EPS.
Separately, Chardan Capital reiterated a “buy” rating and set a $6.00 price objective on shares of Arbutus Biopharma in a research note on Friday.
Arbutus Biopharma Trading Up 1.8 %
NASDAQ ABUS opened at $2.86 on Friday. The stock has a market capitalization of $428.86 million, a price-to-earnings ratio of -6.09 and a beta of 2.26. Arbutus Biopharma has a twelve month low of $1.85 and a twelve month high of $3.22. The stock has a 50-day moving average of $2.70 and a 200 day moving average of $2.46.
Institutional Trading of Arbutus Biopharma
About Arbutus Biopharma
Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.
- Get a free copy of the StockNews.com research report on Arbutus Biopharma (ABUS)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.